CoreWeave and Nebius cite AI compute shortages and higher-priced GPU renewals, but older-chip utilization and depreciation vary across…
S MBI Deep Dives Aug 14 9 clicks
Options strategies will manage portfolio risk after Meta, Alphabet and Amazon calls drove gains, while Lululemon LEAPs produced an 80% loss.
S MBI Deep Dives Aug 13 8 clicks
Zoetis’s U.S. companion-animal revenue fell 6% as dermatology competition drove rebates and discounts, pushing full-year net pricing to…
S scuttleblurb Aug 13 10 clicks
Copart faces a near-term lift from pricier AV repairs and total losses, but shrinking accident volumes could eventually force its…
S Bearhold Research Aug 13 10 clicks
GFL’s proposed acquisition of Secure follows 19% revenue growth at Secure and 14.8% EBITDA growth at GFL, with Permian produced-water and…
S 310 Value’s Newsletter Aug 12 12 clicks
Glenn Schorr and Ken Worthington discuss risks in private-credit software loans, agentic AI at retail brokers, crypto use cases and bank…
YT Steve Eisman Aug 10 14 clicks
Figma raised its 2026 revenue growth guide to 39%, but a roughly 1% sequential 3Q outlook and unchanged $125-135 million operating-income…
S MBI Deep Dives Aug 10 11 clicks
Alphabet's Google Cloud swung from a $3.1 billion operating loss in 2021 to $13.9 billion profit in 2025 as Search revenue grew 13.2%.
S Bearhold Research Aug 10 13 clicks
Visa and Mastercard have absorbed digital wallets and BNPL into their networks, using global merchant acceptance to turn supposed…
S scuttleblurb Aug 10 10 clicks
Steve Eisman reviews SpaceX earnings, AI capital spending’s drag on free cash flow, Meta’s struggles, and the collapse of Situational…
YT Steve Eisman Aug 7 15 clicks
ASTS · short AST SpaceMobile is priced for a 2026 commercial launch despite no identified path to manufacture or launch its satellite deployment target.
BL Value Investors Club Apr 29 11 clicks
Justice Department remedies could bar Google from using location data it cannot share, weakening targeted ads and traffic routing despite…
S John Hempton's Newsletter Oct 9 5 clicks
Alnylam’s 2022 50% phase-three gain faces FDA advisory-panel scrutiny over its amyloidosis drug’s label extension.
S John Hempton's Newsletter Sep 12 1 click